MapLight Therapeutics (MPLT) Change in Accured Expenses (2024 - 2025)

MapLight Therapeutics (MPLT) reported Change in Accured Expenses of $1.1 million for Q4 2025, down 6.72% on a YoY basis from $1.2 million in Q4 2024, and down 6.72% sequentially from $1.2 million in Q4 2024.

MapLight Therapeutics (MPLT) Change in Accured Expenses (2024 - 2025) Analysis & Trends

MapLight Therapeutics (MPLT) has 2 years of Change in Accured Expenses data on file, last reported at $1.1 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 1.13 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -16.82 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 23.10 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 107.70 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -16.74 Mn
10 MapLight Therapeutics 305.82 Mn 305.82 Mn - 1.12 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 1.12 Mn
Dec 31, 2025 1.12 Mn
Dec 31, 2024 1.21 Mn
Dec 31, 2024 1.21 Mn